Moderna Stock Rises After mRNA Flu Shot Approval -- WSJ
Dow Jones2026/08/06 13:56By Xavier Martinez
Shares in Moderna ticked higher after the biotech secured Food and Drug Administration approval for its mRNA flu vaccine for use in adults aged 50 and older.
The FDA's decision capped an arduous seven-month process that included a rare refusal by the regulator to consider the shot. The agency agreed to review it after Moderna said it would conduct a follow-up trial confirming the vaccine's effectiveness among the elderly.
This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).
(END) Dow Jones Newswires
August 06, 2026 09:56 ET (13:56 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Report: Zimbabwe suspends antimony and tungsten exports to promote domestic processing
Germany's AfD's Election Surge Puts Its Pro-Bitcoin Agenda Back in Focus
Mobimo outlines 2026-2030 strategy built on development, investment and trading pillars
Rackspace Technology Insider Sold Shares Worth $1,600,917, According to a Recent SEC Filing
Crypto prices
More
